Clinical Trial Update: Mesenchymal Stem Cell Infusion as Prevention for Graft Rejection and Graft-versus-host Disease [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating mesenchymal stem cell infusion to prevent graft rejection and graft-versus-host disease in hematologic malignancies has comple…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hematologic Malignancies

Drugs mentioned

• Mesenchymal Stem Cell Infusion

Snippet

Sponsor: University of Liege | Conditions: Hematological Malignancies | Phase 2 | Status: COMPLETED